AXSM

Axsome Therapeutics, Inc. [AXSM] Stock Forecast

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?
RSI : 000

AXSM Stock Summary

Top 10 Correlated ETFs

AXSM


Top 10 Correlated Stocks

AXSM


In the News

07:44 29 Mar 2024 AXSM

3 Strong Buy Biotech Stocks to Add to Your Q2 Must-Watch List

Biotech has seen its fair share of ups and downs, including a massive surge during the pandemic followed by a considerable dip. However, the industry will never go too far away from center stage as diseases and conditions will always need medicine and technology to treat them.

12:26 29 Mar 2024 AXSM

Axsome's (AXSM) Narcolepsy Drug Study Meets Primary Goal

Data from a late-stage study shows that a five-week treatment with Axsome's (AXSM) experimental narcolepsy drug reduced weekly cataplexy attacks by 83%, compared to 66% for placebo.

06:55 29 Mar 2024 AXSM

Axsome Therapeutics sleep disorder therapy succeeds in late-stage trial

Axsome Therapeutics said on Monday its therapy for a sleep disorder met the main goal of a late-stage study.

06:45 29 Mar 2024 AXSM

Buying These Dirt-Cheap Stocks Could Be a Brilliant Move

Many investors appear to be underestimating Axsome Therapeutics. CRISPR Therapeutics has tremendous long-term prospects.

12:36 29 Mar 2024 AXSM

Why Is Axsome (AXSM) Down 4% Since Last Earnings Report?

Axsome (AXSM) reported earnings 30 days ago. What's next for the stock?

01:16 29 Mar 2024 AXSM

Axsome (AXSM) Begins Dosing in Depression Study on Sunosi

Axsome (AXSM) doses the first patient in the phase III PARADIGM study evaluating Sunosi (solriamfetol) for treating major depressive disorder. The stock rises 6%.

07:00 29 Mar 2024 AXSM

Axsome Therapeutics to Present at the Leerink Partners Global Biopharma Conference

NEW YORK, March 05, 2024 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today announced that Herriot Tabuteau, MD, Axsome's Chief Executive Officer, will participate in a fireside chat at the Leerink Partners Global Biopharma Conference on Wednesday, March 13, at 9:20 a.m. Eastern Time at the Fontainebleau in Miami Beach, Florida.

07:00 29 Mar 2024 AXSM

Axsome Therapeutics to Present at the TD Cowen 44th Annual Healthcare Conference

NEW YORK, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today announced that Herriot Tabuteau, MD, Axsome's Chief Executive Officer, will participate in a fireside chat at the TD Cowen 44th Annual Healthcare Conference on Wednesday, March 6, from 9:50-10:20 a.m. Eastern Time at the Marriott Copley Place in Boston, Massachusetts.

08:50 29 Mar 2024 AXSM

3 Biotech Stocks to Buy and Hold for the Next 10 Years

CRISPR Therapeutics' recent major regulatory win could be the first of many. Axsome Therapeutics should ride the wave from its rich late-stage pipeline.

11:41 29 Mar 2024 AXSM

Axsome (AXSM) Stock Falls Despite Q4 Earnings & Revenue Beat

Axsome (AXSM) stock declines despite narrower-than-expected loss in the fourth quarter of 2023. Its sales also beat estimates.

AXSM Financial details

Company Rating
Neutral
Market Cap
3.82B
Income
-
Revenue
-
Book val./share
4.04
Cash/share
8.16
Dividend
-
Dividend %
-
Employees
545
Optionable
No
Shortable
Yes
Earnings
06 May 2024
P/E
-20.55
Forward P/E
-
PEG
-
P/S
19.15
P/B
15.81
P/C
9.78
P/FCF
-29.92
Quick Ratio
4.32
Current Ratio
4.46
Debt / Equity
0.94
LT Debt / Equity
0.93
-
-
EPS (TTM)
-
EPS next Y
-
EPS next Q
-1.18
EPS this Y
8.44%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
-
-
-
-
-
SMA20
-2.47%
SMA50
-9.2%
SMA100
25.4%
Inst Own
69.39%
Inst Trans
0.84%
ROA
-35%
ROE
-108%
ROC
-0.39%
Gross Margin
91%
Oper. Margin
-85%
Profit Margin
-93%
Payout
-
Shs Outstand
47.37M
Shs Float
38.78M
-
-
-
-
Target Price
90.67
52W Range
55.02-98.4
52W High
-18.57%
52W Low
+45.09%
RSI
54
Rel Volume
0.63
Avg Volume
770.6K
Volume
487.58K
Perf Week
-1.31%
Perf Month
-14.02%
Perf Quarter
13.38%
Perf Half Y
10.13%
-
-
-
-
Beta
1.161
-
-
Volatility
1.34%, 4.28%
Prev Close
0%
Price
79.8
Change
0.23%

AXSM Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2023-12-31

Metric History 2019-12-312020-12-312021-12-312022-12-31 2023-12-31
2.02K2.02K2.02K2.02K2.02K
Revenue per share
0001.235.96
Net income per share
-2.05-2.83-3.59-4.86-5.27
Operating cash flow per share
-1.36-2.11-2.88-2.87-3.19
Free cash flow per share
-1.36-2.11-2.89-2.88-3.21
Cash per share
6.474.942.34.948.5
Book value per share
-5.17-7.49-10.882.694.2
Tangible book value per share
5.253.06-10.880.972.77
Share holders equity per share
-5.17-7.49-10.882.694.2
Interest debt per share
0.621.421.472.514.09
Market cap
3.52B3.03B1.42B3.14B3.62B
Enterprise value
3.32B2.9B1.38B3.03B3.42B
P/E ratio
-50.46-28.76-10.53-15.86-15.11
Price to sales ratio
00062.6713.36
POCF ratio
-75.82-38.64-13.13-26.91-24.92
PFCF ratio
-75.8-38.61-13.09-26.75-24.82
P/B Ratio
-19.99-10.87-3.4728.6218.93
PTB ratio
-19.99-10.87-3.4728.6218.93
EV to sales
00060.5512.62
Enterprise value over EBITDA
-49.42-29.24-11.1-17.72-19.4
EV to operating cash flow
-71.51-36.93-12.79-26-23.54
EV to free cash flow
-71.49-36.91-12.76-25.85-23.45
Earnings yield
-0.02-0.03-0.09-0.06-0.07
Free cash flow yield
-0.01-0.03-0.08-0.04-0.04
Debt to equity
-0.11-0.18-0.120.860.94
Debt to assets
0.090.27-0.150.290.3
Net debt to EBITDA
2.981.350.290.621.13
Current ratio
97.853.752.543.63
Interest coverage
-54.25-38.64-21.89-24.06-28.34
Income quality
0.680.760.830.620.61
Dividend Yield
0000.010
Payout ratio
000-0.220
Sales general and administrative to revenue
00000
Research and developement to revenue
0001.160.36
Intangibles to total assets
0000.210.11
Capex to operating cash flow
0000.010
Capex to revenue
000-0.010
Capex to depreciation
-0.43-0.59-0.27-0.13-0.09
Stock based compensation to revenue
0000.750.23
Graham number
15.4421.8529.6317.1722.32
ROIC
0.440.450.36-0.91-0.49
Return on tangible assets
-0.32-0.570.4-0.76-0.46
Graham Net
5.2430.420.231.49
Working capital
195.88M160.59M63.45M149.08M365.41M
Tangible asset value
178.72M113.79M-409.2M39.59M125.65M
Net current asset value
178.55M111.68M15.68M23.72M107M
Invested capital
-0.11-0.18-0.120.860.94
Average receivables
00018.85M66.26M
Average payables
7.32M12.22M13.33M25.88M39.64M
Average inventory
0002.16M9.73M
Days sales outstanding
000275127.9
Days payables outstanding
107K63.42K4.15K2.71K451.32
Days of inventory on hand
000303.37167.92
Receivables turnover
0001.332.85
Payables turnover
00.010.090.130.81
Inventory turnover
0001.22.17
ROE
0.40.380.33-1.81-1.25
Capex per share
00-0.01-0.02-0.01

Quarterly Fundamentals Overview

Last date of statement is 2023-12-31 for Q4

Metric History 2022-12-312023-03-312023-06-302023-09-30 2023-12-31
2.02K2.02K2.02K2.02K2.02K
Revenue per share
0.562.191.071.231.51
Net income per share
-1.54-0.26-1.54-1.32-2.08
Operating cash flow per share
-0.63-0.13-1.27-1.14-0.64
Free cash flow per share
-0.64-0.14-1.27-1.14-0.64
Cash per share
4.625.7110.028.848.16
Book value per share
2.522.596.395.724.04
Tangible book value per share
0.911.014.824.32.65
Share holders equity per share
2.522.596.395.724.04
Interest debt per share
2.213.484.33.923.56
Market cap
3.35B2.66B3.13B3.29B3.77B
Enterprise value
3.24B2.56B2.88B3.06B3.57B
P/E ratio
-12.55-59.31-11.67-13.24-9.55
Price to sales ratio
137.528.1467.1256.9852.66
POCF ratio
-121.58-457.18-56.63-61.5-124.07
PFCF ratio
-120.79-451.67-56.49-61.07-124.04
P/B Ratio
30.5923.811.2412.2219.72
PTB ratio
30.5923.811.2412.2219.72
EV to sales
133.1427.0961.7152.9849.87
Enterprise value over EBITDA
-60.43-516.21-50.19-49.29-30.3
EV to operating cash flow
-117.73-440.21-52.07-57.18-117.49
EV to free cash flow
-116.96-434.91-51.94-56.79-117.46
Earnings yield
-0.020-0.02-0.02-0.03
Free cash flow yield
-0.010-0.02-0.02-0.01
Debt to equity
0.861.320.660.690.94
Debt to assets
0.290.380.30.310.3
Net debt to EBITDA
1.9819.94.43.721.7
Current ratio
2.543.024.524.463.63
Interest coverage
-42.13-2.89-23.8382.069.18
Income quality
0.450.520.820.860.31
Dividend Yield
00.020.0100
Payout ratio
0-4.72-0.44-0.020
Sales general and administrative to revenue
4.010.561.120.950
Research and developement to revenue
0.60.190.440.50.43
Intangibles to total assets
0.210.180.110.110.11
Capex to operating cash flow
0.010.0100.010
Capex to revenue
-0.0100-0.010
Capex to depreciation
-0.09-0.04-0.1-0.210
Stock based compensation to revenue
0.440.140.340.260.26
Graham number
9.343.8914.8813.0313.76
ROIC
-0.3-0.03-0.14-0.14-0.25
Return on tangible assets
-0.26-0.03-0.12-0.12-0.19
Graham Net
0.220.163.663.161.43
Working capital
149.08M203.8M404.71M397.1M365.41M
Tangible asset value
39.59M43.41M210.26M202.57M125.65M
Net current asset value
23.72M27.08M186.85M180.41M107M
Invested capital
0.861.320.660.690.94
Average receivables
29M41.25M56.1M72.91M86.62M
Average payables
25.72M37.19M39.36M36.03M34.89M
Average inventory
3.21M6.13M8.6M9.62M12.56M
Days sales outstanding
139.2242.63129.91122.11119.3
Days payables outstanding
1.52K426.06840.67400.92496.22
Days of inventory on hand
169.7194.57181.06137.58184.62
Receivables turnover
0.652.110.690.740.75
Payables turnover
0.060.210.110.220.18
Inventory turnover
0.530.950.50.650.49
ROE
-0.61-0.1-0.24-0.23-0.52
Capex per share
000-0.010

AXSM Frequently Asked Questions

What is Axsome Therapeutics, Inc. stock symbol ?

Axsome Therapeutics, Inc. is a US stock , located in New york of Ny and trading under the symbol AXSM

Is Axsome Therapeutics, Inc. buy or a sell ?

12 stock analysts have 12 predictions with a medium analyst target price of $81.83. The lowest prediction is $25 and the highest is $150

What is AXSM stock prediction ?

With a median analyst target price of $108.5, 2 stock analysts have made 2 forecasts in last 90 days. $108 is the lowest and $109 is the greatest projection.

What is Axsome Therapeutics, Inc. stock quote today ?

Axsome Therapeutics, Inc. stock price is $79.8 today.

Is Axsome Therapeutics, Inc. stock public?

Yes, Axsome Therapeutics, Inc. is a publicly traded company.

Something similar

Top by Market Cap
Top Correlated ETFs
Top Correlated Stocks